



LAB #: F000000-0000-0
 PATIENT: Sample Patient
 ID: P0000000000
 SEX: Male
 DOB: _____

AGE: 4

CLIENT #: 12345
 DOCTOR:
 Doctor's Data, Inc.
 3755 Illinois Ave.
 St. Charles, IL 60174 U.S.A.

Comprehensive Stool Analysis / Parasitology x3

BACTERIOLOGY CULTURE

Expected/Beneficial flora

3+ Bacteroides fragilis group
 4+ Bifidobacterium spp.
 NG Escherichia coli
 NG Lactobacillus spp.
 NG Enterococcus spp.
 NG Clostridium spp.
 NG = No Growth

Commensal (Imbalanced) flora

1+ Beta strep, not group A or B
 2+ Citrobacter freundii complex
 1+ Citrobacter freundii complex, isolate 2
 2+ Enterobacter cloacae complex
 3+ Gamma hemolytic strep
 1+ Staphylococcus aureus

Dysbiotic flora

BACTERIA INFORMATION

Expected /Beneficial bacteria make up a significant portion of the total microflora in a healthy & balanced GI tract. These beneficial bacteria have many health-protecting effects in the GI tract including manufacturing vitamins, fermenting fibers, digesting proteins and carbohydrates, and propagating anti-tumor and anti-inflammatory factors.

Clostridia are prevalent flora in a healthy intestine. Clostridium spp. should be considered in the context of balance with other expected/beneficial flora. Absence of clostridia or over abundance relative to other expected/beneficial flora indicates bacterial imbalance. If *C. difficile* associated disease is suspected, a Comprehensive Clostridium culture or toxigenic *C. difficile* DNA test is recommended.

Commensal (Imbalanced) bacteria are usually neither pathogenic nor beneficial to the host GI tract. Imbalances can occur when there are insufficient levels of beneficial bacteria and increased levels of commensal bacteria. Certain commensal bacteria are reported as dysbiotic at higher levels.

Dysbiotic bacteria consist of known pathogenic bacteria and those that have the potential to cause disease in the GI tract. They can be present due to a number of factors including: consumption of contaminated water or food, exposure to chemicals that are toxic to beneficial bacteria; the use of antibiotics, oral contraceptives or other medications; poor fiber intake and high stress levels.

YEAST CULTURE

Normal flora

No yeast isolated

Dysbiotic flora

MICROSCOPIC YEAST

Result:
Expected: None - Rare

The microscopic finding of yeast in the stool is helpful in identifying whether there is proliferation of yeast. Rare yeast may be normal; however, yeast observed in higher amounts (few, moderate, or many) is abnormal.

YEAST INFORMATION

Yeast normally can be found in small quantities in the skin, mouth, intestine and mucocutaneous junctions. Overgrowth of yeast can infect virtually every organ system, leading to an extensive array of clinical manifestations. Fungal diarrhea is associated with broad-spectrum antibiotics or alterations of the patient's immune status. Symptoms may include abdominal pain, cramping and irritation. When investigating the presence of yeast, disparity may exist between culturing and microscopic examination. Yeast are not uniformly dispersed throughout the stool, this may lead to undetectable or low levels of yeast identified by microscopy, despite a cultured amount of yeast. Conversely, microscopic examination may reveal a significant amount of yeast present, but no yeast cultured. Yeast does not always survive transit through the intestines rendering it unviable.

Comments:

Date Collected: 01/28/2015
 Date Received: 01/30/2015
 Date Completed: 02/06/2015

* *Aeromonas, Campylobacter, Plesiomonas, Salmonella, Shigella, Vibrio, Yersinia, & Edwardsiella tarda* have been specifically tested for and found absent unless reported.





LAB #: F000000-0000-0
 PATIENT: Sample Patient
 ID: P0000000000
 SEX: Male
 DOB:

AGE: 4

CLIENT #: 12345
 DOCTOR:
 Doctor's Data, Inc.
 3755 Illinois Ave.
 St. Charles, IL 60174 U.S.A.

Comprehensive Stool Analysis / Parasitology x3

PARASITOLOGY/MICROSCOPY *
<p>Sample 1 None Ova or Parasites</p>
<p>Sample 2 None Ova or Parasites</p>
<p>Sample 3 None Ova or Parasites</p>
<p>*A trichrome stain and concentrated iodine wet mount slide is read for each sample submitted.</p>

PARASITOLOGY INFORMATION
<p>Intestinal parasites are abnormal inhabitants of the gastrointestinal tract that have the potential to cause damage to their host. The presence of any parasite within the intestine generally confirms that the patient has acquired the organism through fecal-oral contamination. Damage to the host includes parasitic burden, migration, blockage and pressure. Immunologic inflammation, hypersensitivity reactions and cytotoxicity also play a large role in the morbidity of these diseases. The infective dose often relates to severity of the disease and repeat encounters can be additive.</p> <p>There are two main classes of intestinal parasites, they include protozoa and helminths. The protozoa typically have two stages; the trophozoite stage that is the metabolically active, invasive stage and the cyst stage, which is the vegetative inactive form resistant to unfavorable environmental conditions outside the human host. Helminths are large, multicellular organisms. Like protozoa, helminths can be either free-living or parasitic in nature. In their adult form, helminths cannot multiply in humans.</p> <p>In general, acute manifestations of parasitic infection may involve diarrhea with or without mucus and or blood, fever, nausea, or abdominal pain. However these symptoms do not always occur. Consequently, parasitic infections may not be diagnosed or eradicated. If left untreated, chronic parasitic infections can cause damage to the intestinal lining and can be an unsuspected cause of illness and fatigue. Chronic parasitic infections can also be associated with increased intestinal permeability, irritable bowel syndrome, irregular bowel movements, malabsorption, gastritis or indigestion, skin disorders, joint pain, allergic reactions, and decreased immune function.</p> <p>In some instances, parasites may enter the circulation and travel to various organs causing severe organ diseases such as liver abscesses and cysticercosis. In addition, some larval migration can cause pneumonia and in rare cases hyper infection syndrome with large numbers of larvae being produced and found in every tissue of the body.</p> <p>One negative parasitology x1 specimen does not rule out the possibility of parasitic disease, parasitology x3 is recommended. This exam is not designed to detect <i>Cryptosporidium</i> spp, <i>Cyclospora cayetanensis</i> or <i>Microsporidia</i> spp.</p>

GIARDIA/CRYPTOSPORIDIUM IMMUNOASSAY			
	Within	Outside	Reference Range
Giardia intestinalis	Neg		Neg
Cryptosporidium	Neg		Neg

Giardia intestinalis (lamblia) is a protozoan that infects the small intestine and is passed in stool and spread by the fecal-oral route. Waterborne transmission is the major source of giardiasis.

Cryptosporidium is a coccidian protozoa that can be spread from direct person-to-person contact or waterborne transmission.

Comments:

Date Collected: 01/28/2015
 Date Received: 01/30/2015
 Date Completed: 02/06/2015



LAB #: F000000-0000-0
 PATIENT: Sample Patient
 ID: P0000000000
 SEX: Male
 DOB: AGE: 4

CLIENT #: 12345
 DOCTOR:
 Doctor's Data, Inc.
 3755 Illinois Ave.
 St. Charles, IL 60174 U.S.A.

Comprehensive Stool Analysis / Parasitology x3

DIGESTION / ABSORPTION

	Within	Outside	Reference Range
Elastase	440		> 200 µg/mL
Fat Stain	Few		None - Mod
Muscle fibers	None		None - Rare
Vegetable fibers	Rare		None - Few
Carbohydrates	Neg		Neg

Elastase findings can be used for the diagnosis or the exclusion of exocrine pancreatic insufficiency. Correlations between low levels and chronic pancreatitis and cancer have been reported. **Fat Stain:** Microscopic determination of fecal fat using Sudan IV staining is a qualitative procedure utilized to assess fat absorption and to detect steatorrhea. **Muscle fibers** in the stool are an indicator of incomplete digestion. Bloating, flatulence, feelings of "fullness" may be associated with increase in muscle fibers. **Vegetable fibers** in the stool may be indicative of inadequate chewing, or eating "on the run". **Carbohydrates:** The presence of reducing substances in stool specimens can indicate carbohydrate malabsorption.

INFLAMMATION

	Within	Outside	Reference Range
Lactoferrin	2.6		< 7.3 µg/mL
Calprotectin*		68	10 - 50 µg/g
Lysozyme*	271		<= 600 ng/mL
White Blood Cells	None		None - Rare
Mucus	Neg		Neg

Lactoferrin and **Calprotectin** are reliable markers for differentiating organic inflammation (IBD) from functional symptoms (IBS) and for management of IBD. Monitoring levels of fecal lactoferrin and calprotectin can play an essential role in determining the effectiveness of therapy, are good predictors of IBD remission, and can indicate a low risk of relapse. **Lysozyme*** is an enzyme secreted at the site of inflammation in the GI tract and elevated levels have been identified in IBD patients. **White Blood Cells (WBC)** and **Mucus** in the stool can occur with bacterial and parasitic infections, with mucosal irritation, and inflammatory bowel diseases such as Crohn's disease or ulcerative colitis.

IMMUNOLOGY

	Within	Outside	Reference Range
Secretory IgA*		39.7	51 - 204 mg/dL

Secretory IgA* (sIgA) is secreted by mucosal tissue and represents the first line of defense of the GI mucosa and is central to the normal function of the GI tract as an immune barrier. Elevated levels of sIgA have been associated with an upregulated immune response.

Comments:

Date Collected: 01/28/2015
 Date Received: 01/30/2015
 Date Completed: 02/06/2015

*For Research Use Only. Not for use in diagnostic procedures.

Methodology: Elisa, Microscopy, Colormetric, Gas Chromatography, ph Electrode



LAB #: F000000-0000-0
 PATIENT: Sample Patient
 ID: P0000000000
 SEX: Male
 DOB: _____

AGE: 4

CLIENT #: 12345
 DOCTOR:
 Doctor's Data, Inc.
 3755 Illinois Ave.
 St. Charles, IL 60174 U.S.A.

Comprehensive Stool Analysis / Parasitology x3

SHORT CHAIN FATTY ACIDS

	Within	Outside	Reference Range
% Acetate	51		40 - 75 %
% Propionate	25		9 - 29 %
% Butyrate	20		9 - 37 %
% Valerate	4.6		0.5 - 7 %
Butyrate	2.0		0.8 - 4.8 mg/mL
Total SCFA's	9.9		4 - 18 mg/mL

Short chain fatty acids (SCFAs): SCFAs are the end product of the bacterial fermentation process of dietary fiber by beneficial flora in the gut and play an important role in the health of the GI as well as protecting against intestinal dysbiosis. Lactobacilli and bifidobacteria produce large amounts of short chain fatty acids, which decrease the pH of the intestines and therefore make the environment unsuitable for pathogens, including bacteria and yeast. Studies have shown that SCFAs have numerous implications in maintaining gut physiology. SCFAs decrease inflammation, stimulate healing, and contribute to normal cell metabolism and differentiation. Levels of **Butyrate** and **Total SCFA** in mg/mL are important for assessing overall SCFA production, and are reflective of beneficial flora levels and/or adequate fiber intake.

INTESTINAL HEALTH MARKERS

	Within	Outside	Reference Range
Red Blood Cells	None		None - Rare
pH	7.0		6 - 7.8
Occult Blood	Neg		Neg

Red Blood Cells (RBC) in the stool may be associated with a parasitic or bacterial infection, or an inflammatory bowel condition such as ulcerative colitis. Colorectal cancer, anal fistulas, and hemorrhoids should also be ruled out.
pH: Fecal pH is largely dependent on the fermentation of fiber by the beneficial flora of the gut.
Occult blood: A positive occult blood indicates the presence of free hemoglobin found in the stool, which is released when red blood cells are lysed.

MACROSCOPIC APPEARANCE

	Appearance	Expected
Color	Brown	Brown
Consistency	Soft	Formed/Soft

Color: Stool is normally brown because of pigments formed by bacteria acting on bile introduced into the digestive system from the liver. While certain conditions can cause changes in stool color, many changes are harmless and are caused by pigments in foods or dietary supplements. **Consistency:** Stool normally contains about 75% water and ideally should be formed and soft. Stool consistency can vary based upon transit time and water absorption.

INTRODUCTION

This analysis of the stool specimen provides fundamental information about the overall gastrointestinal health of the patient. When abnormal microflora or significant aberrations in intestinal health markers are detected, specific interpretive paragraphs are presented. If no significant abnormalities are found, interpretive paragraphs are not presented.

Imbalanced flora

Imbalanced flora are those bacteria that reside in the host gastrointestinal tract and neither injure nor benefit the host. Certain dysbiotic bacteria may appear under the imbalances category if found at low levels because they are not likely pathogenic at the levels detected. When imbalanced flora appear, it is not uncommon to find inadequate levels of one or more of the beneficial bacteria and/or a fecal pH which is more towards the alkaline end of the reference range (6 - 7.8). It is also not uncommon to find hemolytic or mucoid *E. coli* with a concomitant deficiency of beneficial *E. coli* and alkaline pH, secondary to a mutation of beneficial *E. coli* in alkaline conditions (DDI observations). Treatment with antimicrobial agents is unnecessary unless bacteria appear under the dysbiotic category.

Mackowiak PA. The normal microbial flora. *N Engl J Med.* 1982;307(2):83-93.

Secretory IgA (sIgA)

The concentration of sIgA is abnormally low in this specimen. Immunological activity in the gastrointestinal tract can be assessed using secretory immunoglobulin A (sIgA). Secretory IgA is the predominant antibody, or immune protein the body manufactures and releases in external secretions such as saliva, tears, and milk [1]. It is also transported through the epithelial cells that line the intestines out into the lumen. Secretory IgA represents the first line of defense of the GI mucosa and is central to the normal function of the GI tract as an immune barrier [1]. As the principal immunoglobulin isotype present in mucosal secretions, sIgA plays an important role in controlling intestinal milieu which is constantly presented with potentially harmful antigens such as pathogenic bacteria, parasites, yeast, viruses, abnormal cell antigens, and allergenic proteins [1]. Secretory IgA antibodies exert their function by binding to antigenic epitopes on the invading microorganism, limiting their mobility and adhesion to the epithelium of the mucus membrane [2]. This prevents the antigens from reaching systemic circulation and allowing them to be excreted directly in the feces.

Mental and physical stress as well as inadequate nutrition have been associated with low fecal sIgA concentrations. This includes dietary restrictions, excessive alcohol intake, body mass loss, negative moods, and anxiety [3]. One study found depressed levels of sIgA in malnourished children, particularly protein malnourishment, that responded well to nutritional rehabilitation with a significant increase in sIgA [4]. This may be because the synthesis and expression of sIgA requires adequate intake of the amino acid L-glutamine [3]. Animal studies have demonstrated that a glutamine-restricted diet can result in a 50% decrease in sIgA levels [5]. An increase of dietary L-glutamine can restore GI immune function by protection of cells that synthesize sIgA [6]. *Saccharomyces boulardii* is a nonpathogenic yeast that has been used for the treatment of acute infectious enteritis and antibiotic-associated diarrhea

[7]. Significantly elevated levels of sIgA and subsequent enhanced host immune response have been found following *S. boulardii* administration in mice and rats [8,9].

References:

1. Crago SS, Tomasi TB. Mucosal Antibodies, Food Allergy and Intolerance. Bailliere Tindall/W.B. Saunders 1987;167-89.
2. Roberts JA. Factors predisposing to urinary tract infections in children. *Ped Neph* 1996;10:517-522.
3. Carins J, Booth C. Salivary immunoglobulin-A as a marker of stress during strenuous physical training. *Aviat Space Environ Med* 2002;73(12):1203-7.
4. Teodosio MR, Oliveira ECM. Urinary secretory IgA after nutritional rehabilitation. *Braz J Med Biolog Res* 1999;32:421-426
5. Alverdy J. Effects of glutamine-supplemented diets on immunology of the gut. *J Parent Enteral Nutr* 1990;14(4):1095-1135.
6. Burke DJ, et al. Glutamine-supplemented total parenteral nutrition improves gut function. *Arch Surg* 1989;24:2396-2399.
7. Alverdy JA. The effect of total parenteral nutrition on gut lamina propria cells. *J Parent. Enteral Nutr* 1990;14(suppl).
8. Qamar A, Aboudola S, Warny M, et al. *Saccharomyces boulardii* stimulates intestinal immunoglobulin A immune response to clostridium difficile toxin A in mice. *Infect Immun* 2001;69(4):2762-5.
9. Buts JP, Bernasconi P, Vaerman JP, et al. Stimulation of secretory IgA and secretory component of immunoglobulins in small intestine of rats treated with *Saccharomyces boulardii*. *Dig Dis Sci* 1990;35(2):251-6.

Beneficial Flora

One or more of the expected or beneficial bacteria are low in this specimen. Normally abundant include lactobacilli, bifidobacteria, clostridia, *Bacteroides fragilis* group, enterococci, and some strains of *Escherichia coli*. The beneficial flora have many health-protecting effects in the gut, and as a consequence, are crucial to the health of the whole organism. Some of the roles of the beneficial flora include digestion of proteins and carbohydrates, manufacture of vitamins and essential fatty acids, increase in the number of immune system cells, break down of bacterial toxins and the conversion of flavinoids into anti-tumor and anti-inflammatory factors. Lactobacilli, bifidobacteria, clostridia, and enterococci secrete lactic acid as well as other acids including acetate, propionate, butyrate, and valerate. This secretion causes a subsequent decrease in intestinal pH, which is crucial in preventing an enteric proliferation of microbial pathogens, including bacteria and yeast. Many GI pathogens thrive in alkaline environments. Lactobacilli also secrete the antifungal and antimicrobial agents lactocidin, lactobacillin, acidolin, and hydrogen peroxide. The beneficial flora of the GI have thus been found useful in the inhibition of microbial pathogens, prevention and treatment of antibiotic associated diarrhea, prevention of traveler's diarrhea, enhancement of immune function, and inhibition of the proliferation of yeast.

In a healthy balanced state of intestinal flora, the beneficial flora make up a significant proportion of the total microflora. Healthy levels of each of the beneficial bacteria are indicated

by either a 3+ or 4+ (0 to 4 scale). However, some individuals have low levels of beneficial bacteria and an overgrowth of nonbeneficial (imbalances) or even pathogenic microorganisms (dysbiosis). Often attributed to the use of antibiotics, individuals with low beneficial bacteria may present with chronic symptoms such as irregular transit time, irritable bowel syndrome, bloating, gas, chronic fatigue, headaches, autoimmune diseases (e.g., rheumatoid arthritis), and sensitivities to a variety of foods. Treatment may include the use of probiotic supplements containing various strains of lactobacillus and bifidobacterium species and consumption of cultured or fermented foods including yogurt, kefir, miso, tempeh and tamari sauce. Polyphenols in green and ginseng tea have been found to increase the numbers of beneficial bacteria. If dysbiosis is present, treatment may also include the removal of pathogenic bacteria, yeast, or parasites.

Percival M. Intestinal Health. Clin Nutr In. 1997;5(5):1-6.

Fuller R. Probiotics in Human Medicine. Gut. 1991;32: 439-442.

Siitonen S, Vapaatalo H, Salminen S, et al. Effect of Lactobacilli GG Yoghurt in Prevention of Antibiotic Associated Diarrhea. Ann Med. 1990; 22:57-59.

Oksanen P, Salminen S, Saxelin M, et al. Prevention of Travelers' Diarrhea by Lactobacillus GG. Ann Med. 1990; 22:53-56.

Perdigon G, Alvarez M, et al. The Oral Administration of Lactic Acid Bacteria Increases the Mucosal Intestinal Immunity in Response to Enteropathogens. J Food Prot. 1990;53:404-410.

Valeur, N, et al. Colonization and Immunomodulation by Lactobacillus reuteri ATCC 55730 in the Human Gastrointestinal Tract. Appl Environ. Microbiol. 2004 Feb; 70(2):1176-81.

Elmer G, Surawicz C, and McFarland L. Biotherapeutic agents - a Neglected Modality for the Treatment and Prevention of Intestinal and Vaginal Infections. JAMA. 1996; 275(11):870-876.

Fitzsimmons N and Berry D. Inhibition of Candida albicans by Lactobacillus acidophilus: Evidence for Involvement of a Peroxidase System. Microbio. 1994; 80:125-133

Weisburger JH. Proc Soc Exp Biol Med 1999;220(4):271-5.

Fecal Calprotectin

The level of fecal Calprotectin is higher than expected. Elevated fecal Calprotectin and Lactoferrin levels indicate the presence of neutrophils and inflammation in the gastrointestinal (GI) mucosa. Calprotectin and Lactoferrin facilitate differentiation between irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD). IBD includes autoimmune conditions such as Crohns disease and ulcerative colitis (UC); these conditions may become life-threatening and require lifelong treatment.

For patients 4 years old to adults (Manz 2012; Fagerberg 2005):

High levels of Calprotectin (> 200 µg/gm) are associated with active IBD and gastrointestinal

inflammation; elevation may also occur due to bacterial infection, colitis or sometimes, cancer. Fecal Calprotectin should be reassessed after about 4 weeks for confirmation.

Moderate calprotectin (50-200 µg/gm) is an indicator of chronic inflammation. Inflammation at this level may be due to IBD in remission or inflammation caused by non-steroidal anti-inflammatories (NSAIDs). Levels should be reassessed after about 4 weeks. Low levels of Calprotectin (< 50 µg/gm) are usually associated with viral GI infections or non-inflammatory bowel conditions such as IBS.

Multiple studies have shown fecal Calprotectin and Lactoferrin to be equivalent with respect to clinical sensitivity and specificity. Studies suggest that Calprotectin may correlate more closely with histological (cell microscopy) findings. Lactoferrin may correlate better to macroscopic (endoscopy) findings, and may be the better indicator of impending relapse, elevating 2-3 weeks prior to clinical symptoms.

Chronic inflammation of the gastrointestinal mucosa contributes to symptoms of IBD. Chronic stress is known to contribute to symptom flare-ups and increased inflammation. Liver disease or the use of aspirin or nonsteroidal anti-inflammatory (NSAID) medications may elevate Calprotectin levels. Fecal Calprotectin levels may also be increased in newborns.

References:

Carroccio, Antonio; Iacono, Giuseppe; Cottone, Mario; Di Prima, Lidia; Cartabellotta, Fabio et al. (2003) Diagnostic Accuracy of Fecal Calprotectin Assay in Distinguishing Organic Causes of Chronic Diarrhea from Irritable Bowel Syndrome: A Prospective Study in Adults and Children
Clin. Chem. vol. 49 (6) p. 861-867

Fagerberg, Ulrika Lorentzon; Lööf, Lars; Myrdal, Urban; Hansson, Lars-Olof; Finkel, Yigael
Colorectal Inflammation is Well Predicted by Fecal Calprotectin in Children with Gastrointestinal Symptoms
Journal of Pediatric Gastroenterology & Nutrition: April 2005 - Volume 40 - Issue 4 - pp 450-455

Lamb, C.A.; Mansfield, J.C. (2011)
Measurement of faecal calprotectin and lactoferrin in inflammatory bowel disease.
Frontline gastroenterology vol. 2 (1) p. 13 - 18

Manz, Michael; Burri, Emanuel; Rothen, Claude; Tchanguizi, Nuschin; Niederberger, Christian et al. (2012) Value of fecal calprotectin in the evaluation of patients with abdominal discomfort: an observational study. BMC gastroenterology vol. 12 p. 5

Said, Hesham Ezz El Din, et al. (2013)
The diagnostic value of faecal calprotectin in differentiating inflammatory bowel diseases (IBD) from irritable bowel syndrome (IBS)
Report and Opinion, 2011;3(1)

Vieira, Andrea; Fang, Chia; Rolim, Ermani; Klug, Wilmar; Steinwurz, Flavio et al. (2009)
Inflammatory bowel disease activity assessed by fecal calprotectin and lactoferrin: correlation with laboratory parameters, clinical, endoscopic and histological indexes
BMC Research Notes vol. 2 (1) p. 221




LAB#: F000000-0000-0
PATIENT: Sample Patient
ID: PATIENT-S-00000
SEX: Male
AGE: 51

CLIENT#: 12345
DOCTOR:
Doctor's Data, Inc.
3755 Illinois Ave.
St. Charles, IL 60174

Helicobacter Pylori Stool Antigen

H. pylori



The HpSA enzyme immunoassay (EIA) is an in vitro qualitative procedure for the detection of H. Pylori antigens in the stool. Test results are intended to aid the diagnosis of H. Pylori infection, and to monitor response during and post therapy.

Date Collected: **10/12/2006**
Date Received: **10/13/2006**
Date Completed: **10/14/2006**

Comments:

INTRODUCTION

This analysis of the stool specimen provides fundamental information about the overall gastrointestinal health of the patient. When abnormal microflora or significant aberrations in intestinal health markers are detected, specific interpretive paragraphs are presented. If no significant abnormalities are found, interpretive paragraphs are not presented.



LAB #: F000000-0000-0
PATIENT: Sample Patient
ID: P000000000
SEX: Female
AGE: 5

CLIENT #: 12345
DOCTOR:
Doctor's Data, Inc.
3755 Illinois Ave.
St. Charles, IL 60174

C. difficile culture; stool

RESULTS

	Within	Outside	Reference Interval
<i>C. difficile</i> culture		3+	NG / No Growth

INFORMATION

Clostridium difficile (*C. difficile*) is a gram-positive anaerobic bacterium recognized as a major cause of antibiotic associated diarrhea and colitis. Infection is not uncommon in individuals who have taken broad spectrum antibiotics that eliminate beneficial/competing bacteria. Risk for infection is increased in individuals housed in places where *C. difficile* is prevalent (e.g. hospitals, chronic care facilities). *C. difficile* is ubiquitous in nature and has been isolated from soil, sand, animal feces, and water. Approximately half of all healthy neonates carry *C. difficile* asymptomatically during their first year of life; the carrier rate decreases to about 3% in asymptomatic adults. *C. difficile* associated disease is not overtly expressed unless the bacteria actively produce toxins A and B. If the culture is positive for *C. difficile*, a molecular diagnostic assay utilizing DNA amplification technology which can detect all known strains of toxigenic *C. difficile* will be performed at no additional cost to determine toxigenicity.

SPECIMEN DATA

Comments:

Date Collected: 9/25/2011
Date Received: 9/28/2011
Date Completed: 10/6/2011

V04.11